Table 2.
PAH clinical variables according to cfDNA tertile in Cohort B
| cfDNA Tertile | |||||||
|---|---|---|---|---|---|---|---|
| Low Tertile | Middle Tertile | High Tertile | |||||
| Variable | N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | P-value** |
| Age | 54 | 61 (52–71) | 53 | 59 (48–73) | 54 | 59 (48–71) | 0.99 |
| Body mass index | 52 | 25.5 (21.6–30.2) | 53 | 25.6 (22.0–31.1) | 54 | 29.6 (24.5–32.6) | 0.02 |
| REVEAL 2.0 | 54 | 6 (4–7) | 53 | 8 (7–9) | 54 | 8 (6–9) | <0.0001 |
| REVEAL Lite 2 | 54 | 6 (4–7) | 53 | 7 (6–8) | 54 | 7 (6–8) | 0.0004 |
| mPAP (mmHg) | 54 | 35 (26–50) | 53 | 45 (36–52) | 54 | 48 (42–58) | 0.0001 |
| RAP (mmHg) | 54 | 9 (6–12) | 53 | 9 (6–11) | 54 | 11 (8–15) | 0.007 |
| PAWP (mmHg) | 54 | 7 (5–11) | 53 | 7 (5–12) | 54 | 10 (7–16) | 0.01 |
| PVR (Wood units) | 54 | 5.7 (3.2–8.9) | 53 | 7.0 (4.9–11.1) | 54 | 8.3 (6.0–10.2) | 0.005 |
| Cardiac output (L/min) | 54 | 4.7 (4.0–5.7) | 53 | 4.9 (3.3–6.2) | 54 | 4.5 (3.7–5.5) | 0.58 |
| Heart rate (bpm) | 54 | 76 (67–90) | 53 | 83 (72–95) | 54 | 80 (65–89) | 0.12 |
| SBP (mmHg) | 54 | 119 (111–131) | 53 | 122 (110–139) | 54 | 125 (117–136) | 0.31 |
| 6MWD (meters) | 51 | 450 (269–488) | 46 | 312 (152–413) | 39 | 290 (152–439) | 0.003 |
| NYHA | 54 | 2 (2–3) | 53 | 3 (2–3) | 53 | 3 (2–3) | 0.09 |
| BNP (pg/mL) | 53 | 64 (23–191) | 51 | 143 (62–465) | 54 | 264 (112–734) | <0.0001 |
| hs-Troponin T (ng/L) | 27 | 11.29 (6.65–17.90) | 32 | 13.99 (10.41–20.78) | 22 | 24.89 (13.35–38.18) | 0.002 |
| hs-CRP (mg/L) | 29 | 2.5 (0.8–4.2) | 33 | 6.5 (4.2–15.4) | 23 | 7.3 (4.1–36.0) | <0.0001 |
| Creatinine (mg/dL) | 48 | 0.91 (0.73–1.06) | 51 | 0.93 (0.80–1.21) | 47 | 0.94 (0.79–1.16) | 0.36 |
Subjects were divided into cfDNA tertiles as Low (cfDNA ≤ 28.99 ng/mL), Middle (28.99 < cfDNA ≤ 61.12 ng/mL) or High Tertile (cfDNA > 61.12 ng/mL)
For each variable, differences across cfDNA tertiles were assessed by Kruskal-Wallis test.
Abbreviations: PAH, pulmonary arterial hypertension; cfDNA, cell-free DNA; REVEAL, Registry to Evaluate Early and Long-Term PAH Disease Management; mPAP, mean pulmonary artery pressure; RAP, right atrial pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; SBP, systolic blood pressure; 6MWD, six-minute walk distance; NYHA, New York Heart Association; BNP, brain-type natriuretic peptide; hs, high-sensitivity; CRP, C-reactive protein.